Prescient Therapeutics Share Price and Company Fundamentals



Price
$0.195
Change
0.015 (8.333%)
52 week
0.054 - 0.285

Last traded: Yesterday at 6:10 AM

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

5.57

Dividend yield

Beta

0.83

Market cap

$125.3M

Enterprise value

$96.83M

Company profile

Primary activitiesBio-pharmaceutical research and development investment.
Industry / SectorBiotechnology / Healthcare
Websitehttp://ptxtherapeutics.com
Mailing address100 Albert Road Level 4 Melbourne VIC 3205 Australia
Phone / Fax61 3 9692 7222 / 61 3 9077 9233
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Prescient Therapeutics does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Prescient Therapeutics.

NameTitleAgeTotal Pay
Mr. Yatomi-Clarke Steven LeeMD, CEO & Director501.29k
Ms. Melanie Jaye Leydin B.Bus, C.A., CACFO & Company Sec.47114k
Dr. Terrence G. ChewChief Medical Officer73155.99k
Ms. Leanne WestDirector of Clinical Affairs & Operations
Dr. James D. Winkler Ph.D.Head of Bus. Devel.65

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-327.81%

Return on assets

-12.26%

Return on equity

-19.50%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Prescient Therapeutics is 125.3M and its enterprise value is 96.83M. The enterprise value to revenue ratio of PTX is 89.82.

The PTX's stocks Beta value is 0.83 making it 17% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Prescient Therapeutics (PTX)

Prescient Therapeutics (ASX:PTX) Frequently Asked Questions

1. What is Prescient Therapeutics's Stock Symbol?

Prescient Therapeutics trades on ASX under the ticker symbol "PTX".

2. What is Prescient Therapeutics's stock price today?

One share of PTX stock can currently be purchased for approximately $0.195.

3. How can I contact Prescient Therapeutics?

Prescient Therapeutics's mailing address is 100 Albert Road Level 4 Melbourne VIC 3205 Australia. The company can be reached via phone at 61 3 9692 7222.

4. What is Prescient Therapeutics's official website?

The official website of Prescient Therapeutics is http://ptxtherapeutics.com.

5. Which share registry manages Prescient Therapeutics's stock?

Prescient Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.